A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive chronic lymphocytic leukemia

被引：0
|
作者：
Kittai, Adam
Allan, John
James, Dan
Bridge, Helen
Miranda, Miguel
Yong, Alan
Fam, Fady
Roos, Jack
Shetty, Vikram
Skarbnik, Alan
Davids, Matthew
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1550098
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [41] Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: Three-Year Follow-Up
    O'Brien, Susan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (07) : 13 - 15
  • [42] SEQUOIA: Results of a Phase 3 Randomised Study of Zanubrutinib versus Bendamustine plus Rituximab in Patients with Treatment-Naive Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma
    Munir, Talha
    Giannopoulos, Krzysztof
    Jurczak, Wojciech
    Simkovic, Martin
    Shadman, Mazyar
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia
    Opat, Stephen
    Chan, Henry
    Ciepluch, Hanna
    Greil, Richard
    Tani, Monica
    Trneny, Marek
    Brander, Danielle M.
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Kahl, Brad S.
    Ghia, Paolo
    Li, Jianyong
    Tian, Tian
    Zhou, Lei
    Marimpietri, Carol
    Paik, Jason C.
    Cohen, Aileen
    Huang, Jane
    Brown, Jennifer R.
    Robak, Tadeusz
    Tam, Constantine S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 95 - 96
  • [43] Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up.
    Woyach, Jennifer Ann
    Rogers, Kerry Anne
    Bhat, Seema Ali
    Blachly, James Stewart
    Jianfar, Mojgan
    Frigault, Melanie M.
    Hamdy, Ahmed M.
    Izumi, Raquel
    Munugalavadla, Veerendra
    Quah, Cheng Seok
    Min Hui Wang
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Acalabrutinib with Obinutuzumab in Treatment-Naive (TN) and Relapsed/Refractory (R/R) Patients with Chronic Lymphocytic Leukemia (CLL): 3-Year Follow-Up
    Woyach, Jennifer A.
    Rogers, Kerry A.
    Bhat, Seema
    Blachly, James
    Jianfar, Mojgan
    Frigault, Melanie M.
    Hamdy, Ahmed
    Izumi, Raquel
    Munugalavadla, Veerendra
    Quah, Cheng
    Wang, Min Hui
    Byrd, John C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S281 - S281
  • [45] COMPARATIVE EFFICACY OF IBRUTINIB MONOTHERAPY VERSUS OBINUTUZUMAB PLUS CHLORAMBUCIL IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC)
    Sanden, S., V
    Diels, J.
    Cote, S.
    Baculea, S.
    VALUE IN HEALTH, 2017, 20 (05) : A210 - A210
  • [46] Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis
    Cohan, Stanley
    Tencer, Tom
    Arndorfer, Stella
    Zhu, Xuelian
    Zivkovic, Marko
    Kumar, Jinender
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
  • [47] Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis
    Strand, Vibeke
    McInnes, Iain
    Mease, Philip
    Nash, Peter
    Thom, Howard
    Kalyvas, Chrysostomos
    Hunger, Matthias
    Gandhi, Kunal
    Pricop, Luminita
    Jugl, Steffen
    Choy, Ernest
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (07) : 497 - 510
  • [48] Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib
    Garcia-Foncillas, J.
    Bokemeyer, C.
    Italiano, A.
    Keating, K.
    Paracha, N.
    Fellous, M.
    Marian, M.
    Fillbrunn, M.
    Gao, W.
    Ayyagari, R.
    Lassen, U. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S401 - S401
  • [49] Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
    Shadman, Mazyar
    Tedeschi, Alessandra
    Mohseninejad, Leyla
    Yang, Keri
    Lamanna, Nicole
    Xu, Sheng
    Cohen, Aileen Cleary
    Challagulla, Swetha
    Xue, Mei
    Williams, Rhys
    O'Brien, Susan M.
    Brown, Jennifer R.
    Tam, Constantine S.
    BLOOD, 2023, 142
  • [50] Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
    Shadman, Mazyar
    Tedeschi, Alessandra
    Mohseninejad, Leyla
    Yang, Keri
    Lamanna, Nicole
    Xu, Sheng
    Cohen, Aileen
    Challagulla, Swetha
    Xue, Mei
    Williams, Rhys
    O'Brien, Susan M.
    Brown, Jennifer R.
    Tam, Constantine
    BLOOD CANCER JOURNAL, 2024, 14 (01):
12345